Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Recruiting

Phase 2

Phase 3

EIK1001-006 & PembroSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Sponsor:

Eikon Therapeutics

Code:

NCT06697301

Conditions

Advanced Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

EIK1001

Pembrolizumab (KEYTRUDA® )

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-26. This information was provided to ClinicalTrials.gov by Eikon Therapeutics on 2025-11-12.